Humacyte Reports Revenue Growth to $406,000 in Q2 2026 Amid Ongoing Losses

Humacyte, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $406,000, a significant increase from $301,000 in the same period last year. The company generated $899,000 in revenue for the first half of 2026, compared to $818,000 for the first half of 2025. The revenue growth is attributed primarily to product sales of its FDA-approved product, Symvess, which was launched in March 2025 for use in vascular trauma. However, the company continues to face substantial operating losses, reporting a net loss of $36.8 million for the second quarter, slightly improved from a loss of $37.7 million in the prior year. For the first half of 2026, the net loss was $54.4 million, compared to a profit of $1.5 million in the same period of 2025.

Operating expenses for the second quarter decreased to $27.4 million from $30.0 million year-over-year, driven by a reduction in research and development costs, which fell to $18.1 million from $22.0 million. The decrease in R&D expenses was primarily due to lower material costs associated with non-commercial manufacturing production runs. General and administrative expenses remained relatively stable at $8.0 million. The cost of goods sold also increased significantly to $1.2 million, reflecting inventory reserves and production costs associated with Symvess.

In terms of strategic developments, Humacyte has made notable progress in its clinical trials and partnerships. The company is currently conducting Phase 3 trials for its 6 millimeter ATEV in AV access for hemodialysis and has received Fast Track designation from the FDA for this indication. Additionally, the company announced a workforce reduction plan in May 2026, which is expected to yield approximately $14.3 million in net savings. This decision was made to align the organizational structure with business objectives and improve cash runway.

As of June 30, 2026, Humacyte reported cash and cash equivalents of $79.9 million, an increase from $50.5 million at the end of 2025. The company has also entered into various financing agreements, including a recent public offering that raised approximately $53.8 million. However, the company cautioned that it may not have sufficient liquidity to fund operations beyond one year if it fails to generate adequate cash flows from product sales or secure additional capital. The company’s accumulated deficit has reached $781.3 million, highlighting the ongoing financial challenges it faces as it seeks to commercialize its products and advance its clinical pipeline.

Looking ahead, Humacyte plans to continue its focus on the commercialization of Symvess and the advancement of its product candidates. The company is also exploring additional funding options, including equity and debt financing, to support its operations and growth initiatives. The management remains optimistic about the potential of its bioengineered human tissues to transform the practice of medicine, despite the inherent risks and uncertainties associated with the biotechnology industry.